Genmab Announces Plans for sBLA Submission to the FDA
Company Announcement
Genmab A/S, renowned for its innovative approaches in biotechnology, is poised to submit a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) in the first half of 2025. This application will propose the use of subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2), targeted for adult patients suffering from relapsed or refractory follicular lymphoma (FL) after at least one prior treatment.
Positive Phase 3 Trial Results
The impetus for this upcoming submission stems from encouraging outcomes observed in the Phase 3 EPCORE FL-1 trial, where the combination of epcoritamab and R2 demonstrated a significant overall response rate (ORR) of p-value < 0.0001. These initial findings were further validated during an assessment by an Independent Data Monitoring Committee (IDMC).
Advancing Patient Care
“We are excited about the robust data supporting our upcoming sBLA submission. Our commitment to advancing innovative therapies for patients is paramount,” expressed Dr. Jan van de Winkel, Chief Executive Officer of Genmab. “The results of the EPCORE study highlight the potential of epcoritamab in transforming treatment options for patients facing relapsed or refractory FL.”
Safety Profile and Future Plans
The safety profile of the therapeutic combination has shown consistency with existing safety recognitions of the individual drugs. No novel safety issues emerged during the trial, reinforcing confidence as Genmab plans to submit comprehensive results at a medical conference in the following year.
Understanding Follicular Lymphoma (FL)
Follicular lymphoma is identified as a slow-growing type of non-Hodgkin lymphoma, accounting for a significant percentage of lymphoma cases. In the U.S. alone, around 15,000 new cases of FL are diagnosed annually. Despite various treatment modalities, FL is often deemed incurable with current therapies, leading to heightened demand for innovative treatments like epcoritamab.
The Challenge of Treatment Resistance
Patients battling FL frequently endure relapses, with each recurrence potentially shortening the duration of remission and lengthening the timeline to subsequent treatment. Alarmingly, over 25% of individuals may evolve from FL to an aggressive form known as diffuse large B-cell lymphoma (DLBCL), impacting their prognosis adversely.
Exploring the EPCORE FL-1 Trial
The EPCORE FL-1 trial is a Phase 3 open-label study assessing the safety and effectiveness of epcoritamab in combination with R2. This clinical trial is pivotal as it seeks to establish a new standard for treating relapsed or refractory FL.
About Epcoritamab's Mechanism
Epcoritamab is an innovative bispecific antibody employing Genmab's proprietary DuoBody technology. This groundbreaking approach aims to engage T-cells in targeting CD20+ B-cells, amplifying the immune response against cancerous cells.
Genmab's Growth and Commitment
Headquartered in Copenhagen, Denmark, Genmab has established its reputation over the last two decades in developing next-generation antibody innovations. Its ambition to reshape cancer therapy through its KYSO antibody medicines initiative underscores their dedication to improving patient outcomes.
Continuing Collaborations and Research
Genmab and AbbVie continue to spearhead research on epcoritamab across various hematologic malignancies. With several ongoing Phase 3 trials, both entities are committed to exploring the full potential of epcoritamab as both a monotherapy and in combinatorial strategies.
Frequently Asked Questions
What is the main goal of Genmab’s sBLA submission?
The primary goal is to gain FDA approval for epcoritamab as a treatment option for adults with relapsed or refractory follicular lymphoma.
How does epcoritamab work?
Epcoritamab is designed to bind to CD3 on T-cells and CD20 on B-cells, promoting T-cell-mediated killing of malignant B-cells.
What are the primary findings from the EPCORE FL-1 trial?
The trial demonstrated a positive overall response rate, meeting one of its primary endpoints with a statistically significant p-value.
Is epcoritamab currently approved for use?
Yes, epcoritamab is approved as a monotherapy for patients who have undergone two or more lines of systemic therapy.
What is Genmab’s vision for the future?
Genmab envisions transforming cancer treatment through innovative antibody therapies, aiming for significant advancements by 2030.
